{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:30:08Z","timestamp":1781299808515,"version":"3.54.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Plaque psoriasis is a persistent skin disorder that necessitates efficient management. This study investigates the therapeutic effectiveness and timeline for skin lesion resolution in plaque psoriasis patients treated with combined biologic agents compared to standard therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Conducted retrospectively between March 2020 and March 2023, the study included 162 patients with moderate to severe plaque psoriasis. Participants were divided into two groups: the Control Group, which received standard treatments, and the Combined Biologic Agent Group, which received additional biologic therapy with secukinumab. Participants in the Control Group received standard treatments, while those in the Combined Biologic Agent Group received standard treatments plus secukinumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The results showed that the Combined Biologic Agent Group experienced a significantly faster onset of therapeutic effects, with an average time of 3.04\u2009\u00b1\u20092.25\u2009days compared to 6.12\u2009\u00b1\u20092.06\u2009days in the Control Group. Additionally, skin lesion resolution occurred more rapidly in the biologic agent group (7.04\u2009\u00b1\u20092.13\u2009days) than in the control group (14.56\u2009\u00b1\u20094.73\u2009days). By week 24, the Psoriasis Area and Severity Index (PASI) scores demonstrated a more substantial reduction in the biologic agent group, decreasing from 26.98\u2009\u00b1\u200911.28 to 2.48\u2009\u00b1\u20093.01, whereas the control group showed a reduction from 25.82\u2009\u00b1\u200910.47 to 10.40\u2009\u00b1\u20097.63. The overall effectiveness rate was higher in the biologic agent group, with no cases of ineffectiveness, compared to a 20.99% ineffectiveness rate in the control group. Furthermore, there was no recurrence of the disease in the biologic agent group, while the control group experienced an 11.11% recurrence rate. Both groups had a similar incidence of adverse reactions, indicating that the addition of biologic agents does not significantly increase the risk of adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>These findings suggest that combined biologic agent therapy offers a more effective and faster treatment option for plaque psoriasis without compromising safety. However, larger-scale clinical trials are necessary to validate these results and establish the long-term benefits and safety of this treatment approach in diverse patient populations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1451069","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T05:03:06Z","timestamp":1726635786000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative effectiveness of combined biologic agents versus standard therapies in the treatment of plaque psoriasis: a retrospective analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Bo","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"ref3","first-page":"S14","article-title":"The skin in psoriasis: assessment and challenges","volume":"33","author":"Oji","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: a brief overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: what is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and Oral treatments for plaque psoriasis: a Meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/1203475418814234","article-title":"Comparison of management guidelines for moderate-to-severe plaque psoriasis: a review of phototherapy, systemic therapies, and biologic agents","volume":"23","author":"Ighani","year":"2019","journal-title":"J Cutan Med Surg"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2174\/1573397115666181130094455","article-title":"Combination therapy of Apremilast and biologic agent as a safe option of psoriatic arthritis and psoriasis","volume":"15","author":"Metyas","year":"2019","journal-title":"Curr Rheumatol Rev"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3390\/biomedicines10051058","article-title":"Hong SP: comparison of the efficacy and safety of biologics (Secukinumab, Ustekinumab, and Guselkumab) for the treatment of moderate-to-severe psoriasis: real-world data from a single Korean center","volume":"10","author":"Jung","year":"2022","journal-title":"Biomedicines"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s13555-024-01182-4","article-title":"Long-term effectiveness and safety of Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: a five-year multicenter retrospective study\u2014IL PSO (Italian landscape psoriasis)","volume":"14","author":"Valenti","year":"2024","journal-title":"Dermatol Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/jpm14020186","article-title":"Effectiveness and safety of biological therapies in very severe plaque psoriasis: a real-life retrospective study","volume":"14","author":"Fiorillo","year":"2024","journal-title":"J Personal Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.36849\/jdd.7481","article-title":"A review of Tapinarof: novel topical treatment for plaque psoriasis in adults","volume":"22","author":"Kalabalik-Hoganson","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"ref15","first-page":"309","article-title":"Childhood psoriasis","volume":"64","author":"Farber","year":"1999","journal-title":"Cutis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40261-017-0550-z","article-title":"Novel biologic agents targeting Interleukin-23 and Interleukin-17 for moderate-to-severe psoriasis","volume":"37","author":"Chen","year":"2017","journal-title":"Clin Drug Investig"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1517\/14712598.2013.851192","article-title":"Biologic agents in nail psoriasis: efficacy data and considerations","volume":"13","author":"Kyriakou","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40261-017-0603-3","article-title":"A review of switching biologic agents in the treatment of moderate-to-severe plaque psoriasis","volume":"38","author":"Hu","year":"2018","journal-title":"Clin Drug Investig"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2340\/00015555-2276","article-title":"Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: a systematic review","volume":"96","author":"Zweegers","year":"2016","journal-title":"Acta Derm Venereol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1451069\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T05:03:07Z","timestamp":1726635787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1451069\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":19,"alternative-id":["10.3389\/fmed.2024.1451069"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1451069","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]},"article-number":"1451069"}}